WO2020259559A1 - Mutant de protéine ge du virus varicelle-zona et son procédé d'expression - Google Patents

Mutant de protéine ge du virus varicelle-zona et son procédé d'expression Download PDF

Info

Publication number
WO2020259559A1
WO2020259559A1 PCT/CN2020/098019 CN2020098019W WO2020259559A1 WO 2020259559 A1 WO2020259559 A1 WO 2020259559A1 CN 2020098019 W CN2020098019 W CN 2020098019W WO 2020259559 A1 WO2020259559 A1 WO 2020259559A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein
cell
gene
vzv
expression vector
Prior art date
Application number
PCT/CN2020/098019
Other languages
English (en)
Chinese (zh)
Inventor
周晨亮
何强
沈巧英
周凌云
江元翔
刘革
曾宪放
史力
莫呈钧
张智
Original Assignee
怡道生物科技(苏州)有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 怡道生物科技(苏州)有限公司 filed Critical 怡道生物科技(苏州)有限公司
Publication of WO2020259559A1 publication Critical patent/WO2020259559A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C07K14/04—Varicella-zoster virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Definitions

  • the invention belongs to the field of biomedicine. Specifically, the invention relates to a recombinant shingles vaccine composition and a preparation method and application thereof.
  • VZV Varicella zoster virus
  • HZ herpes zoster
  • Chickenpox is usually seen in childhood, while herpes zoster does not develop until adulthood. After the primary infection with chickenpox, the virus can be latent in the host's ganglia. With age, immune function impairment or immunosuppression, VZV can be reactivated and cause shingles.
  • herpes zoster The clinical manifestation of herpes zoster is a unilateral vesicular rash.
  • the obvious feature is that it is limited to a single skin segment, usually accompanied by radicular pain.
  • Patients may have obvious pain and discomfort. Symptoms can last for several weeks or months. In severely ill patients, they can even last for several years, resulting in a decline in the quality of life. In rare cases, shingles may not appear as a rash. Complications occur in about 25% of people with shingles, and they increase with age.
  • the most common serious complication is post-herpetic neuralgia (PHN), that is, pain that persists after the acute phase of herpes.
  • PPN post-herpetic neuralgia
  • the incidence of herpes zoster patients is 10%-30%. The pain can be It lasts for several months or even years, seriously affecting the quality of life of patients.
  • the risk factors that affect the onset of shingles are age, immune deficiency, gender
  • VZV Most primary VZV infections occur in childhood, then VZV is latent in the ganglia, and VZV can be reactivated in adulthood. Studies have shown that about 99% of Americans aged 40 and over have serological evidence of VZV infection; 90% of Europeans aged 20-29 years are seropositive for anti-VZV; in some countries in South America, Australia and Asia The primary VZV infection may occur later, but 90% of people over 40 years old will have VZV seropositivity. Therefore, on a global scale, most adults are at risk of developing shingles and its related complications.
  • the global incidence of herpes zoster is (3 ⁇ 5)/1000 person-years, and the Asia- Pacific region is (3 ⁇ 10)/1000 person-years, and it is increasing by 2.5% ⁇ 5.0% year by year, and the hospitalization rate is (2 ⁇ 25)/100,000
  • the mortality rate is (0.017 ⁇ 0.465) per 100,000 person-years, and the recurrence rate is 1% ⁇ 6%.
  • my country is in a state of high-degree aging, and the social and economic burden brought by HZ is increasing year by year.
  • HZ has brought a huge negative impact on the quality of life of patients, especially elderly patients.
  • According to data released by the National Bureau of Statistics it is estimated that the population over 40 years old in 2017 was about 650 million. If the HZ incidence rate is 2.5/1000 person-years, it is conservatively estimated that there are about 1.6 million new cases of HZ in my country each year.
  • HZ live attenuated vaccine Zostavax and HZ subunit vaccine Shingrix are on the market worldwide (HZ live attenuated vaccine Zostavax and HZ subunit vaccine Shingrix).
  • Merck’s Zostavax is a live attenuated vaccine. It contains the same virus strain as the VZV Oka strain used in the varicella vaccine.
  • the vaccine formula uses a minimum potency of 19400 PFU. It was approved by the FDA in 2006 for marketing and has been approved in more than 60 countries.
  • One dose can be subcutaneously administered to people over 50 years of age.
  • Shingrix developed by GlaxoSmithKline is a subunit vaccine based on recombinant gE protein supplemented with a novel adjuvant AS01B.
  • the technical problem to be solved by the present invention is to provide a new VZV gE protein mutant as a candidate antigen for preventing herpes zoster.
  • Another problem to be solved by the present invention is to provide an efficient and economical method for expressing VZV gE protein mutants in CHO cells.
  • the first aspect of the present invention provides a VZV gE protein mutant, which is different from the amino acid sequence of the VZV gE protein included in the NCBI (National Center for Biotechnology Information) database.
  • VZV gE protein wild-type or full-length gE protein is generally 623 amino acids. It consists of the main part of the gE protein containing the signal peptide, the hydrophobic anchor region (residues 546-558) and the C-terminal tail (for example, refer to the literature Davison AJ, Scott J: The complete DNA sequence of varicella-zoster virus. J Gen Virol 1986; 67: 1759-1816). Different studies have slightly different differences in the protein molecular structure of gE protein.
  • the gE protein when using modern biomolecular technology to prepare recombinant VZV gE protein, the gE protein is generally removed (truncated) so that it lacks the carboxy-terminal hydrophobic anchor region (for example, patent CN107106675A, EP0405867B); or called transmembrane region (hydrophobic). Region) and intracellular region (for example, patent CN102517302A).
  • the mutant protein precursor is translated using the translation mechanism in the carrier cell (host cell) and transferred to the cell membrane to be secreted outside the cell, the signal peptide region is usually cut by signal peptidase (for example, patent CN102548578A, CN102711812B).
  • a mutant that can be effectively applied to a recombinant shingles vaccine composition should have a mutation site in the epitope region, that is, in the extracellular region that does not contain a signal peptide (for convenience of description, in the present invention Called mature antigen in Chinese).
  • the anchor region, transmembrane region, intracellular region and signal peptide can be predicted by related application software, such as SignalP (http://www.cbs.dtu.
  • dk/services/SignalP/ predict whether the protein has a signal peptide
  • TMHMM Server V.2.0 http://www.cbs.dtu.dk/services/TMHMM
  • PSORT software can determine the accuracy of the secreted signal peptide and whether the signal peptide cleavage site can be recognized and cleaved.
  • the mutation site of the VZV gE protein mutant is at position 141 of the mature antigen sequence (region), and this site is mutated from leucine to methionine. It should be noted that the VZV gE protein sequence included in the NCBI database indicates that position 141 of the mature antigen region is highly conserved.
  • NCBI Sequence ID Q9J3M8.1 amino acid sequence (full length is 623 amino acids), based on the amino acid sequence, according to the content disclosed in the prior art EP0405867B (appropriate VZV gE antigen is truncated to remove the carboxyl end
  • VZV glycoprotein gE also called gpl
  • the protein sequence generally obtained by expressing proteins in eukaryotic cells will lack the leader sequence (also called signal peptide, positions 1-30) Amino acid), it can be deduced that the mature antigen in the full-length protein is 31-546 positions, and the 141st position is leucine.
  • the inventor of the present application surprisingly discovered that when selecting a specific amino acid sequence as the basis for gene optimization in the process of preparing recombinant gE protein, if the 141th position of the mature antigen region is artificially modified (mutation from leucine to methionine) , Genes and vectors designed based on the modified amino acid sequence will be able to achieve higher antigen expression.
  • the ideal VZV gE protein used in the preparation of recombinant shingles vaccine composition can be as shown in SEQ ID NO: 1, where the sequence 1-30 is the signal peptide region, and the 31-546 is mature
  • the inventors artificially mutated position 141 of the mature antigen region from leucine to methionine.
  • the second aspect of the present invention also provides a recombinant shingles vaccine composition, which contains a gE protein of the VZV virus.
  • a gE protein of the VZV virus contains a gE protein of the VZV virus.
  • the aforementioned gE protein has an amino acid sequence shown in SEQ ID NO: 1 or 3.
  • VZV gE protein is usually achieved through expression in cultured cells or through chemical synthesis.
  • Host cells frequently used and suitable for protein production include E. coli, yeast, insects, and mammals.
  • Expression vectors and host cells are commercially available, and the expression vector contains a promoter and a cloning site for the sequence encoding the protein of interest so that the promoter and sequence are operably linked.
  • Other elements may be present, such as a signal peptide sequence (sometimes called a leader sequence), a tag sequence (e.g., hexa-His), a transcription termination signal, an origin of replication, and a sequence encoding the product.
  • the methods and procedures used to transfect host cells are also well known.
  • a suitable VZV gE antigen is a VZV gE protein that has been truncated to remove the carboxy-terminal anchor region (starting at amino acid 547) (for example, patent CN107106675A, EP0405867B).
  • the expression of protein in eukaryotic cells will generally make the obtained protein sequence lack the signal peptide part (for example, patent CN102548578A, CN102711812B). Therefore, in a typical embodiment, when CHO cells are used to express gE protein, the sequence of gE protein that is finally secreted outside the CHO cell will be as shown in SEQ ID NO: 3.
  • mutants provided by the present invention are not limited to The above two specific sequences can be obtained by those skilled in the art through software prediction methods known in the art and published prior art content. These sequences have similarities with SEQ ID NO:1, namely There is a mutation in the 141th of the mature antigen region (from leucine to methionine). Due to the different sources of VZV virus strains, the difference between these sequences may be 1 or 2 or 3 or 4 amino acids The difference in residues, but these differences will not affect the application of gE protein as an antigen.
  • a gE gene encoding the gE protein of the VZV virus is provided, the gene is a gE gene that can be expressed in CHO cells, and the gene has the nucleoside shown in SEQ ID NO: 2 Acid sequence.
  • an expression vector is provided, and the expression vector contains the sequence of the gE gene.
  • the expression vector is cloned to carry the blasticidin resistance gene by introducing the 5'and 3'ends of the gE gene into the restriction endonuclease sites of XbaI and NotI, respectively.
  • the plasmid expression vector and the plasmid expression vector carrying the bleomycin resistance gene are cloned to carry the blasticidin resistance gene by introducing the 5'and 3'ends of the gE gene into the restriction endonuclease sites of XbaI and NotI, respectively.
  • the expression vector contains the aforementioned gE gene shown in SEQ ID NO: 2.
  • a genetically engineered cell contains the expression vector, or the gE gene shown in SEQ ID NO: 2 is integrated in its genome.
  • the aforementioned cells are CHO cells.
  • the cell is a CHO cell containing the gE gene or expression vector of the present invention, and the cell can express and produce gE protein at a high level.
  • an immunogenic protein the protein is the gE protein of the VZV virus, and the gE protein is expressed by CHO cells.
  • the immunogenic protein is prepared by the following method:
  • the use of the vaccine composition is provided to prevent or treat diseases or disorders related to herpes zoster virus infection.
  • a method for expressing the gE protein of VZV virus in CHO cells which includes the following steps:
  • step (3) Use the cell line obtained in step (3) for expression to obtain VZV protein.
  • the expression vector described in the step (1) is a plasmid expression vector carrying a blasticidin resistance gene and/or a plasmid expression vector carrying a bleomycin resistance gene .
  • the CHO cells used in the step (2) are CHO-K1 cells.
  • a conservative truncated gE protein amino acid sequence was selected as the basis for gene optimization. In order to improve the expression efficiency, only the signal peptide region and mature antigen were selected.
  • the inventor of the present application surprisingly found that when selecting a specific amino acid sequence as the basis for gene optimization in the process of preparing recombinant gE protein, if the 141th position of the mature antigen region is artificially modified (mutated from leucine to methionine) Acid), genes and vectors designed based on the modified amino acid sequence will be able to achieve higher antigen expression.
  • the mutated protein sequence has a total length of 546 amino acids (SEQ ID NO: 1), which is specifically as follows. The sequence includes the signal peptide and the main body of the antigen, but does not include the C-terminal carboxy-terminal anchoring region in the gE protein.
  • the codon preferred by CHO cells is selected to optimize the gE gene (such as SEQ ID NO: 2), and the synthesis is entrusted to an outsourcing company, as follows. It should be noted that the optimization principle is not simply to select the most frequent codon in CHO cells, but a more complex optimization scheme. There are three overall optimization principles: First, according to the degeneracy of the codons, replace the original codons with the high-frequency codons corresponding to each amino acid in CHO cells; second, to avoid excessive GC in the post-transcribed mRNA The content affects its secondary structure, which in turn affects translation efficiency. In the optimization process, try to control the GC% of the gene at 40-60%; third, avoid some commonly used restriction enzyme sites.
  • the 5'and 3'ends of the above synthesized gE gene were introduced into Xba I and Not I restriction endonuclease cleavage sites, respectively, and the fragment was cloned into the expression vectors pWX2.0 and pWX1.0 by PCR.
  • the vector pWX2.0 carries the blasticidin resistance gene
  • pWX1.0 carries the bleomycin resistance gene.
  • Both of these vectors use the cytomegalovirus (CMV) promoter/enhancer sequence to express the target gene.
  • the CMV promoter is a strong promoter commonly used to promote eukaryotic gene expression.
  • the corresponding expression plasmid was obtained by cloning and construction, and the sequence was verified by restriction enzyme digestion and sequencing.
  • construction methods of the above two expression vectors are conventional technical means in the field.
  • construction methods that can be referred to are:
  • the vector pWX2.0 was digested with restriction enzymes Xba I (NEB, Cat. #: R0145S) and Not I-HF (NEB, Cat. #: R3189S), and the digested product with a size of 4775 bp was recovered.
  • the above-mentioned 1660bp recovered fragment was ligated into the above 4775bp pWX2.0 vector, and the ligated product was transformed into TOP10 competent cells, and screened with a plate containing blasticidin to obtain several monoclonal positive colonies, and some of them were selected for PCR Amplification and sequencing verification. Then, pick a clone that was verified by sequencing and streak it twice on the LB plate.
  • step 2.1 using plasmid pUC57-gE as template, double enzyme digestion with Xba I and Not I-HF to obtain a 1660 bp DNA fragment. After separation by 1% agarose gel electrophoresis, the gel was tapped and recovered under UV light. 1660bp DNA fragment.
  • the vector pWX1.0 was double digested with restriction enzymes Xba I and Not I-HF, and a 4172 bp vector fragment was recovered using a gel purification kit. The 1660bp recovered fragment was ligated to the 4172bp pWX1.0 vector fragment, and the ligated product was transformed into TOP10 competent cells. Several single clones were selected and verified by PCR and sequencing.
  • the expression plasmid was prepared in large quantities by the method in 2 above, and linearized and stably transfected into host cell CHO-K1. In this example, a total of 6 sets of transfection experiments were performed. Subsequently, each group of transfected mini cell populations were screened by fed-batch culture, and the cell populations with higher expression levels were selected for subsequent clonal screening by limiting dilution. It can be seen that in all 6 groups of mini cell groups, the average cell expression level is between 2-3g/L, and the expression level of the highest three groups of cells is between 2.5-3g/L, the highest group of cells The protein expression level can be 3.04g/L.
  • the three groups of cell populations with the highest expression levels are selected, and single clones are selected for these three groups of cell populations by limiting dilution.
  • the selected single clones are expanded during the fed-batch culture process, the supernatants of the above cloned cells are collected, and the samples are taken for western blot detection.
  • the target protein is determined according to the bands, and the cloned LDC photos, growth conditions, and expression levels are considered. , Viable cell density, viability, final lactic acid content and related product quality parameters, select the best three clones, that is, the dominant cell line.
  • the cell line obtained above is cultured and expressed in a bioreactor to obtain a cell culture supernatant containing gE protein. Similarly, the above-mentioned supernatant can be sampled for Western blot detection to determine whether it is the target protein according to the band. It has been proved that the average gE protein in the above cell lines can reach 3g/L.
  • the design template is optimized by the same DNA optimization strategy, and the average protein expression of the obtained cell line is about 2.5g/L.
  • the mutant provided by the present invention has immunogenicity equivalent to that of the wild-type protein (detailed below). Therefore, the protein mutants, expression vectors and cell lines containing optimized nucleic acid sequences provided by the present invention will provide a more excellent alternative to the VZV vaccine.
  • the amino acid sequence analysis of the expression product proved that the protein precursor (that is, as the gene When the optimized basic amino acid sequence is secreted outside the cell, the signal peptide region has been cut by the signal peptidase.
  • the VZV gE recombinant protein is shown in SEQ ID NO: 3, and there is an artificial mutation at position 141 of the sequence. The amino acid was mutated to methionine.
  • the method of using CHO cell lines to stably express the VZV gE recombinant protein is a well-known method in the art.
  • the method of using CHO cell lines to stably express the VZV gE recombinant protein is a well-known method in the art.
  • the specific plasmid transfection and cell line construction methods are as follows:
  • CD CHO medium M1 to resuscitate and cultivate 1 CHO-K1 host cell as a working cell bank cell.
  • the plasmids pWX1.0-Z-gE and pWX2.0-B-gE obtained by the above 2 method were linearized, specifically, the restriction enzyme Sca I-HF was used for digestion (50 ⁇ l digestion system ), take 2 ⁇ l of the digested product and use 1% agarose gel electrophoresis to detect it. The results show that the two plasmids after Sca I-HF digestion showed a single and clear band, indicating a good linearization result.
  • the 50 ⁇ l linearized product was purified by phenol chloroform extraction and ethanol precipitation, and then dissolved in 10 mM Tris buffer.
  • the concentration of plasmid pWX1.0-Z-gE was 1285.3ng/ ⁇ l, and the concentration of pWX2.0-B-gE was 1064.3ng/ ⁇ l.
  • the above host cell CHO-K1 was inoculated into the medium M1 at a density of 7 ⁇ 10 5 cells/ml. After 24 hours, the host cells were counted, and the cells were diluted to 1.0 ⁇ 10 6 cells/ml with the pre-warmed medium M1, and then 5ml of the cell suspension was placed in a Kuhner shaker for later use.
  • the parameters of the shaker are: temperature 36.5°C, humidity 85%, carbon dioxide 6%, rotating speed 225rpm. Prepare for transfection, the specific steps are as follows:
  • the stable CHO-K1 cell line containing the optimized gE gene can be obtained by the above-mentioned transfection method.
  • media selection of mini cell populations and selection of monoclonal cells by the limiting dilution method are also well-known experimental methods. Through these methods, monoclonal cells with higher expression levels can be obtained, that is, the dominant CHO cell line.
  • the protein with a purity of 95% or more can be obtained Used as an antigen protein.
  • the above antigens and adjuvants were sucked into a recombinant shingles vaccine composition, and C57BL/6 mice were used as animal models to carry out immunization. Original research.
  • the specific method is: using gE protein as an antigen, using aluminum phosphate and CpG ODN as adjuvants to prepare a recombinant shingles vaccine composition.
  • C57BL/6 mice aged 6-8 weeks were selected to be randomly divided into groups, 10 mice in each group, the above vaccine composition was injected intramuscularly, and the vaccine group and adjuvant group were set up, 0 and 3 weeks were immunized, and the blood was collected in the 5th week.
  • the ELISA method was used to detect the antibody titer (ie total IgG) of the anti-VZV gE protein in the serum, and the ELISPOT method was used to detect the cellular immunity level in the spleen cells, mainly the expression of IFN- ⁇ .
  • the results show that the vaccine combination prepared by the gE protein obtained by the technical solution provided by the present invention has very good immunogenicity and can be used as a potential recombinant shingles vaccine candidate (specific results are shown in Table 1).
  • the immunogenicity evaluation method is a professional technical method in the field.
  • the more specific operation method is as follows:
  • C57BL/6 mice aged 6-8 weeks were selected to be randomly divided into groups, with 10 mice in each group.
  • Different doses of vaccine were injected intramuscularly (see Table 1 for the specific ratio) with an injection volume of 0.05ml; 0 and 3 weeks of immunization, blood was taken from the spleen at the 5th week, serum was separated for ELISA detection of antibodies, and splenic lymphocytes were separated for ELISPOT analysis.
  • the specific detection method can be taken as an example as follows:
  • the antigen gE stock solution was diluted with PBS to 1 ⁇ g/ml, and 100 ⁇ l of the diluted stock solution was added to each well of the ELISA plate. 4°C overnight. Washing machine.
  • Spleens were taken from each group of mice and lymphocytes were separated. The level of IFN- ⁇ expression in mouse spleen lymphocytes was measured by ELISPOT.
  • Coated ELISPOT plate (aseptic operation, performed one day before taking the spleen)
  • mice were sacrificed and immersed in 75% ethanol. Take out the mouse spleen in a clean bench. Put a burned 200-mesh copper mesh in a 35mm petri dish, add 1ml of lymphocyte separation solution, and grind with the plunger of a 1ml syringe. After filtering the suspension with spleen cells through a burned 200-mesh copper mesh, transfer to a 15ml centrifuge tube, add the lymphocyte separation solution to 4ml, and cover the surface with 0.5ml of RPMI1640 basic medium. Room temperature, 800g, speed 3, centrifugation for 30 minutes. Aspirate the lymphocyte layer, add 10ml RPMI1640 basal medium, wash, and centrifuge at 250g at room temperature for 10 minutes. Discard the supernatant, add 2ml RPMI1640 complete medium to resuspend the cells, and count.
  • Add cells Dilute the cells with complete medium to 6 ⁇ 10 6 /ml according to the results of the cell count, and add mAb CD28-A to the cell suspension diluted 1000 times. Add 100 ⁇ l/well to the ELISPOT plate. Positive control: 1 ⁇ l ConA stimulant was added, and the stimulation concentration was 5 ⁇ g/ml. Sample to be tested: add stimulus gE protein peptide library diluted with serum-free medium, final concentration 2 ⁇ g/ml; negative control: no ConA stimulus, nor stimulus short peptide. Incubate at 37°C with 5% CO2 for 24 hours, during which time the culture plate cannot be moved to avoid changes in the cell position and blur of ELISPOT spots.
  • Discard the cell suspension add 200 ⁇ l/well of sterile PBS and wash the plate 5 times. Take 50 ⁇ l of biotin-labeled detection antibody and add it to 10 ml of diluent (PBS+0.1% BSA), mix well, and filter with 0.2 ⁇ m filter. Add 100 ⁇ l to each well and incubate at 37°C for 2 hours. Discard the diluent of the biotin-labeled detection antibody, add 200 ⁇ l/well of sterile PBS and wash the plate 5 times. Dilute the antibody with diluent (PBS+0.1% BSA), take 50 ⁇ l and add 10ml of diluent, mix well, and filter with 0.2 ⁇ m filter.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne un mutant de protéine gE du virus varicelle-zona immunogène et un gène codant pour celui-ci. Par comparaison avec une protéine gE du virus varicelle-zona de type sauvage, le mutant diffère en ce que la leucine est mutée en méthionine en position 141 d'une séquence d'antigène mature. L'invention concerne en outre un procédé de préparation du mutant.
PCT/CN2020/098019 2019-06-28 2020-06-24 Mutant de protéine ge du virus varicelle-zona et son procédé d'expression WO2020259559A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910575791.3A CN112142829B (zh) 2019-06-28 2019-06-28 水痘-带状疱疹病毒gE蛋白突变体及其表达方法
CN201910575791.3 2019-06-28

Publications (1)

Publication Number Publication Date
WO2020259559A1 true WO2020259559A1 (fr) 2020-12-30

Family

ID=73869406

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/098019 WO2020259559A1 (fr) 2019-06-28 2020-06-24 Mutant de protéine ge du virus varicelle-zona et son procédé d'expression

Country Status (2)

Country Link
CN (1) CN112142829B (fr)
WO (1) WO2020259559A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022515271A (ja) * 2019-11-29 2022-02-17 北京▲緑▼竹生物技▲術▼股▲フン▼有限公司 組換え水痘帯状疱疹ウイルスワクチン
CN118146319A (zh) * 2024-05-13 2024-06-07 普大生物科技(泰州)有限公司 一种vzv重组蛋白及其制备方法和应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114958882B (zh) * 2022-05-11 2023-05-26 晟明生物技术(郑州)有限公司 一种表达水痘-带状疱疹病毒gE蛋白的DNA分子
CN115819522B (zh) * 2022-11-19 2023-08-08 广州佰芮慷生物科技有限公司 一种带状疱疹病毒疫苗、表达蛋白及重组腺病毒制备与应用
CN116655748B (zh) * 2023-02-28 2024-07-26 易慧生物技术(上海)有限公司 一种截短型水痘-带状疱疹病毒gE蛋白及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0405867B1 (fr) * 1989-06-27 1995-03-15 SMITHKLINE BEECHAM BIOLOGICALS s.a. Composés
CN109602901A (zh) * 2019-01-08 2019-04-12 成都迈科康生物科技有限公司 一种带状疱疹病毒疫苗及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769239A (en) * 1984-08-21 1988-09-06 Merck & Co., Inc. Vaccine against varicella-zoster virus
MXPA04010902A (es) * 2004-11-03 2006-05-08 Alvaro Raul Lara Rodriguez Vacuna recombinante a partir de las proteinas ge, gi y gb del virus de varicela zoster como tratamiento y prevencion de esclerosis multiple.
KR101723605B1 (ko) * 2014-10-21 2017-04-07 진원생명과학 주식회사 대상포진 예방 및 치료용 dna 백신 조성물 및 이를 이용한 vzv 항원에 대한 t세포 활성화 방법
CN108472309A (zh) * 2015-10-22 2018-08-31 摩登纳特斯有限公司 用于水痘带状疱疹病毒（vzv）的核酸疫苗
CN107022559A (zh) * 2016-12-08 2017-08-08 长春祈健生物制品有限公司 一种水痘‑带状疱疹病毒糖蛋白e胞外区蛋白的制备方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0405867B1 (fr) * 1989-06-27 1995-03-15 SMITHKLINE BEECHAM BIOLOGICALS s.a. Composés
CN109602901A (zh) * 2019-01-08 2019-04-12 成都迈科康生物科技有限公司 一种带状疱疹病毒疫苗及其制备方法和应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MICHELE H. ET AL.: "Purification, characterization and immunogenicity of recombinant varicella-zoster virus glycoprotein gE secreted by Chinese hamster ovary cells", VIRUS RESEARCH, vol. 40, 29 February 1996 (1996-02-29), XP055600497, DOI: 20200908210044 *
MICHELE H. ET AL.: "Purification, characterization and immunogenicity of recombinant varicella-zoster virus glycoprotein gE secreted by Chinese hamster ovary cells", VIRUS RESEARCH, vol. 40, 29 February 1996 (1996-02-29), XP055600497, DOI: 20200908210117A *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022515271A (ja) * 2019-11-29 2022-02-17 北京▲緑▼竹生物技▲術▼股▲フン▼有限公司 組換え水痘帯状疱疹ウイルスワクチン
CN118146319A (zh) * 2024-05-13 2024-06-07 普大生物科技(泰州)有限公司 一种vzv重组蛋白及其制备方法和应用

Also Published As

Publication number Publication date
CN112142829B (zh) 2022-02-22
CN112142829A (zh) 2020-12-29

Similar Documents

Publication Publication Date Title
WO2020259559A1 (fr) Mutant de protéine ge du virus varicelle-zona et son procédé d'expression
CN111821433B (zh) mRNA疫苗及其合成方法、试剂盒
JP3217019B2 (ja) Ｈｃｍｖの糖タンパク質、およびｈｃｍｖワクチンおよびその産生法
US7700114B2 (en) Modified HPV E6 and E7 genes and proteins useful for vaccination
WO2020259558A1 (fr) Gène ge et vecteur pour exprimer un gène
WO2020259609A1 (fr) Composition de vaccin anti-zona recombinant et son application
CN113845576B (zh) 重组猫疱疹病毒1型gB-gD蛋白及其应用
CN112375768A (zh) Covid-19冠状病毒的假病毒及其制备方法和应用
KR20230034933A (ko) Covid-19에 대한 보호를 위한 약독화된 폭스바이러스 벡터 기반 백신
WO2021042947A1 (fr) Conception et utilisation de vaccin à adn minicercle
JP2021518152A (ja) 標的タンパク質を安定して発現できる組換えウイルス
CN115819522B (zh) 一种带状疱疹病毒疫苗、表达蛋白及重组腺病毒制备与应用
KR102715320B1 (ko) 신형 hpv 치료용 핵산 백신
WO2023123696A1 (fr) Marqueur de mutation d'épitope de protéine n pour préparer une souche de vaccin délétée d'épitope de génotype ii de prrsv et son utilisation
CN114703205A (zh) 一种疱疹病毒糖蛋白gE重组蛋白、疫苗、制备方法和应用
Cai et al. Characterization of the duck plague virus UL35 gene
KR101111998B1 (ko) 이종성 요소가 없는 ｇＭ-음성 ＥＨＶ-돌연변이체
Li et al. The CDE region of feline Calicivirus VP1 protein is a potential candidate subunit vaccine
Fujimoto et al. Accumulation of a soluble form of human nectin-2 is required for exerting the resistance against herpes simplex virus type 2 infection in transfected cells
CN115887634B (zh) 鸡传染性支气管炎二价亚单位疫苗及应用
CN1283788C (zh) 表达猪繁殖与呼吸综合征病毒的重组伪狂犬病毒及应用
KR102680105B1 (ko) 코로나19 바이러스 및 인플루엔자 h1n1 바이러스에 대한 바이러스 유사입자 및 이의 용도
EP2230246A1 (fr) Particules similaires au virus 5 de glycoprotéine d'artérivirus
SONG et al. Preparation of Monoclonal Antibody against Major Capsid Protein of Largemouth Bass Iridovirus and Its Epitope Identification
CN111732667B (zh) 小反刍兽疫病毒基因工程亚单位疫苗

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20832037

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20832037

Country of ref document: EP

Kind code of ref document: A1